Nang Kuang Pharmaceutical Co., Ltd. announced that its The Abbreviated New Drug Application for Bendamustine Hydrochloride for Injection USP, 25 mg/vial and 100 mg/vial indicated for the treatment of Chronic lymphocytic leukemia (CLL) and Indolent B-cell non-Hodgkin lymphoma (NHL) has been tentatively approved by the U.S. Food and Drug Administration. The company continues to work on the product development and obtain the drug license to increase the revenue scale.